|
Variable
|
Patients with ADR (n = 217)
|
Patients without ADR (n = 863)
|
P value
|
|---|
|
Age (mean ± SD in years)
|
47.96 ± 16.50
|
40.07 ± 16.51
|
< 0.001†
|
|
Sex
|
|
Male
|
137 (63.1%)
|
593 (68.7%)
|
0.116‡
|
|
Female
|
80 (36.9%)
|
270 (31.3%)
| |
|
History of drug allergy
|
|
Yes
|
5 (2.3%)
|
26 (3.0%)
|
0.576‡
|
|
No
|
212 (97.7%)
|
837 (97.0%)
| |
|
Presence of comorbidity
|
|
Yes
|
117 (53.9%)
|
294 (34.1%)
|
< 0.001‡
|
|
No
|
100 (46.1%)
|
569 (65.9%)
| |
|
COVID-19 category
|
|
Patient under investigation
|
9 (4.1%)
|
80 (9.3%)
| |
|
Stage 1
|
1 (0.5%)
|
35 (4.1%)
| |
|
Stage 2
|
27 (12.4%)
|
357 (41.4%)
| |
|
Stage 3
|
85 (39.1%)
|
311 (36.0%)
| |
|
Stage 4
|
79 (36.4%)
|
58 (6.7%)
| |
|
Stage 5
|
16 (7.4%)
|
22 (2.5%)
| |
|
Number of COVID-19 drug(s)
|
|
1
|
51 (23.5%)
|
704 (81.6%)
| |
|
2
|
96 (44.2%)
|
115 (13.3%)
| |
|
3
|
46 (21.2%)
|
30 (3.5%)
| |
|
4 and 5
|
24 (11.1%)
|
14 (1.6%)
| |
- Data are n (%) or mean (± SD)
- †Analysed with Mann–Whitney U test
- ‡Analysed with Chi-square (X2) test
